Significant renoprotective effect of telbivudine during preemptive antiviral therapy in advanced liver cancer patients receiving cisplatin-based chemotherapy: A case-control study

Scandinavian Journal of Gastroenterology

Volumn 49, Issue 12, 2014, Pages 1456-1464

  Lin, Chih Lang ^a,b   Chien, Rong Nan ^a   Yeh, Charisse ^c   Hsu, Chao Wei ^a   Chang, Ming Ling ^a   Chen, Yi Cheng ^a   Yeh, Chau Ting ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^c Flintridge Sacred Heart Academy   (United States)

Author keywords

Estimated glomerular filtration rate; Fluorouracil; Hepatitis B; Hepatocellular carcinoma; Mitoxantrone

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; CISPLATIN; FLUOROURACIL; MITOMYCIN; PROTECTIVE AGENT; TELBIVUDINE; THYMIDINE;

ACUTE KIDNEY INJURY; ADULT; AGED; ANALOGS AND DERIVATIVES; CARCINOMA, HEPATOCELLULAR; CHEMICALLY INDUCED; COMPLICATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEPATITIS B, CHRONIC; HUMAN; KAPLAN MEIER METHOD; LIVER NEOPLASMS; MALE; MIDDLE AGED; MORTALITY; TREATMENT OUTCOME; VIROLOGY;

ACUTE KIDNEY INJURY; ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; CISPLATIN; FEMALE; FLUOROURACIL; HEPATITIS B, CHRONIC; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; MITOMYCIN; PROTECTIVE AGENTS; THYMIDINE; TREATMENT OUTCOME;

EID: 84914100303     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365521.2014.962604     Document Type: Article

References (30)

1. Yeh CT, Chien RN, Chu CM, Liaw YF. Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy. Hepatology 2000;31:1318-26.
2. Ito K, Arai M, Imazeki F, Yonemitsu Y, Bekku D, Kanda T, et al. Risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Scand J Gastroenterol 2010;45:243-9.
3. Tan TL, Chen WN. A proteomics analysis of cellular proteins associated with HBV genotype-specific HBX: potential in identification of early diagnostic markers for HCC. J Clin Virol 2005;33:293-8.
4. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-917.
5. Yeh CT, Chen HC, Sung CM, Hsu CL, Lin CC, Pan KT, et al. Retrospective comparison between a regular and a splitdose protocol of 5-fluorouracil, cisplatin, and mitoxantrone for the treatment of far advanced hepatocellular carcinoma. BMC Cancer 2011;11:117.
6. Sohn W, Paik YH, Lee MW, Rhim H, Lim HK, Cho JY, et al. Predisposing factors for recurrence of HBV-related small hepatocellular carcinoma after percutaneous radiofrequency ablation. Scand J Gastroenterol 2014;49:373-80.
7. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005;42:1208-36.
8. Tziomalos K. Effect of antiviral treatment on the risk of hepatocellular carcinoma in patients with chronic hepatitis B. World J Hepatol 2010;2:91-3.
9. Liang KH, Lin CC, Yeh CT. GALNT14 SNP as a potential predictor of response to combination chemotherapy using 5-FU, mitoxantrone and cisplatin in advanced HCC. Pharmacogenomics 2011;12:1061-73.
10. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90.
11. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34.
12. Kohrt HE, Ouyang DL, Keeffe EB. Systematic review: lamivudine prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection. Aliment Pharmacol Ther 2006;24:1003-16.
13. Loomba R, Rowley A, Wesley R, Liang TJ, Hoofnagle JH, Pucino F, et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 2008;148:519-28.
14. Guo X, Nzerue C. How to prevent, recognize, and treat druginduced nephrotoxicity. Cleve Clin J Med 2002;69:289-90; 93-4, 96-7 passim.
15. dos Santos NA, Carvalho Rodrigues MA, Martins NM, dos Santos AC. Cisplatin-induced nephrotoxicity and targets of nephroprotection: an update. Arch Toxicol 2012;86: 1233-50.
16. Han X, Yue J, Chesney RW. Functional TauT protects against acute kidney injury. J Am Soc Nephrol 2009;20: 1323-32.
17. Zheng XY, Wei RB, Tang L, Li P, Zheng XD. Meta-analysis of combined therapy for adult hepatitis B virus-associated glomerulonephritis. World J Gastroenterol 2012;18:821-32.
18. Chan HL, Chen YC, Gane EJ, Sarin SK, Suh DJ, Piratvisuth T, et al. Randomized clinical trial: efficacy and safety of telbivudine and lamivudine in treatment-naive patients with HBV-related decompensated cirrhosis. J Viral Hepat 2012;19:732-43.
19. Wang Y, Thongsawat S, Gane EJ, Liaw YF, Jia J, Hou J, et al. Efficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis B. J Viral Hepat 2013; 20:e37-46.
20. Lin CL, Chien RN, Hu CC, Lai MW, Yeh CT. Identification of hepatitis B virus rtS117F substitution as a compensatory mutation for rtM204I during lamivudine therapy. J Antimicrob Chemother 2012;67:39-48.
21. Hsu CW, Yeh CT, Chang ML, Liaw YF. Identification of a hepatitis B virus S gene mutant in lamivudine-treated patients experiencing HBsAg seroclearance. Gastroenterology 2007;132:543-50.
22. Lin CL, Chien RN, Lin SM, Ke PY, Lin CC, Yeh CT. An occult hepatitis B-derived hepatoma cell line carrying persistent nuclear viral DNA and permissive for exogenous hepatitis B virus infection. PLoS One 2013;8:e65456.
23. Woo G, Tomlinson G, Nishikawa Y, Kowgier M, Sherman M, Wong DK, et al. Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses. Gastroenterology 2010;139:1218-29.
24. Biselli M, Andreone P, Gramenzi A, Trevisani F, Cursaro C, Rossi C, et al. Transcatheter arterial chemoembolization therapy for patients with hepatocellular carcinoma: a casecontrolled study. Clin Gastroenterol Hepatol 2005;3: 918-25.
25. Greten TF, Papendorf F, Bleck JS, Kirchhoff T, Wohlberedt T, Kubicka S, et al. Survival rate in patients with hepatocellular carcinoma: a retrospective analysis of 389 patients. Br J Cancer 2005;92:1862-8.
26. Huang YH, Wu JC, Chen SC, Chen CH, Chiang JH, Huo TI, et al. Survival benefit of transcatheter arterial chemoembolization in patients with hepatocellular carcinoma larger than 10 cm in diameter. Aliment Pharmacol Ther 2006;23:129-35.
27. Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 2005;4:307-20.
28. Pabla N, Dong Z. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int 2008;73:994-1007.
29. Arany I, Safirstein RL. Cisplatin nephrotoxicity. Semin Nephrol 2003;23:460-4.
30. Liang K-H, Chen Y-C, Hsu C-W, Chang M-L, Yeh C-T. Decrease of serum angiotensin converting enzyme levels upon telbivudine treatment for chronic hepatitis B virus infection and negative correlations between the enzyme levels and estimated glumerular filtration rates. Hepat Mon 2014; 14:e15074.